B Marasini

Summary

Affiliation: University of Milan
Country: Italy

Publications

  1. ncbi Scleroderma heart disease
    B Marasini
    Rheumatology Unit, Humanitas Clinical Institute, University of Milan, Italy
    Int J Immunopathol Pharmacol 18:609-14. 2005
  2. ncbi Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients
    B Marasini
    Department of Medicine, Surgery and Dentistry, S Paolo Hospital, University of Milan, Milan, Italy
    Ann Rheum Dis 60:1046-9. 2001
  3. ncbi Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon
    B Marasini
    Department of Medicine, Surgery and Dentistry, San Paolo Hospital, University of Milan, Italy
    Scand J Rheumatol 33:253-6. 2004
  4. ncbi Metastatic melanoma in a young woman treated with TNF-α inhibitor for psoriatic arthritis: a case report
    Bianca Marasini
    Rheumatology Unit, IRCCS Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Curr Drug Saf 6:275-6. 2011
  5. ncbi Systemic sclerosis and cancer
    B Marasini
    Rheumatology Unit, IRCCS Istituto Clinico Humanitas, University of Milan, Milan, Italy
    Int J Immunopathol Pharmacol 22:573-8. 2009
  6. ncbi Homocysteine concentration in primary and systemic sclerosis associated Raynaud's phenomenon
    B Marasini
    Department of Medicine, Surgery and Dentistry, Institute of Radiological Sciences, San Paolo Hospital, Italy
    J Rheumatol 27:2621-3. 2000
  7. ncbi Myocardial involvement in systemic sclerosis
    L Belloli
    Rheumatology Unit, IRCCS Humanitas Clinical Institute, University of Milan, Milan, Italy
    Rheumatology (Oxford) 47:1070-2. 2008
  8. ncbi Interstitial lung disease in systemic sclerosis
    B Marasini
    Rheumatology Unit, Humanitas Clinical Institute, IRCCS, University of Milan, Italy
    Int J Immunopathol Pharmacol 20:223-8. 2007
  9. ncbi Statins and cardiovascular risk in rheumatic diseases
    B Marasini
    Rheumatology Unit, IRCCS Humanitas Clinical Institute, Rozzano Milan, Italy
    Int J Immunopathol Pharmacol 25:25-30. 2012
  10. ncbi Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity
    M Massarotti
    Rheumatology Unit, IRCCS Humanitas Clinical Institute, University of Milan, Rozzano, Milan, Italy
    Int J Immunopathol Pharmacol 22:547-9. 2009

Collaborators

Detail Information

Publications10

  1. ncbi Scleroderma heart disease
    B Marasini
    Rheumatology Unit, Humanitas Clinical Institute, University of Milan, Italy
    Int J Immunopathol Pharmacol 18:609-14. 2005
    ..Treatment options will be reviewed, even though no cure for systemic sclerosis exists, and the current therapy of diastolic dysfunction remains unsatisfactory...
  2. ncbi Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients
    B Marasini
    Department of Medicine, Surgery and Dentistry, S Paolo Hospital, University of Milan, Milan, Italy
    Ann Rheum Dis 60:1046-9. 2001
    ..To establish the frequency of connective tissue diseases (CTD) in a cohort of Italian patients with primary biliary cirrhosis (PBC) and to evaluate the availability of a marker for the early identification of the more common associated CTD...
  3. ncbi Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon
    B Marasini
    Department of Medicine, Surgery and Dentistry, San Paolo Hospital, University of Milan, Italy
    Scand J Rheumatol 33:253-6. 2004
    ..We evaluated whether there are differences between iloprost and alprostadil, in terms of either clinical efficacy or of laboratory data, with the aim of assisting in the treatment of connective tissue disease (CTD)-associated RP...
  4. ncbi Metastatic melanoma in a young woman treated with TNF-α inhibitor for psoriatic arthritis: a case report
    Bianca Marasini
    Rheumatology Unit, IRCCS Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Curr Drug Saf 6:275-6. 2011
    ..In contrast with the extensive literature on cancer risk in rheumatoid arthritis, little has been reported on the development of malignancies in spondyloarthroparthies...
  5. ncbi Systemic sclerosis and cancer
    B Marasini
    Rheumatology Unit, IRCCS Istituto Clinico Humanitas, University of Milan, Milan, Italy
    Int J Immunopathol Pharmacol 22:573-8. 2009
    ..Continuing interest in these associations, in particular in the different modalities of associations, may help to understand the underlying biological mechanisms and to identify patients at risk...
  6. ncbi Homocysteine concentration in primary and systemic sclerosis associated Raynaud's phenomenon
    B Marasini
    Department of Medicine, Surgery and Dentistry, Institute of Radiological Sciences, San Paolo Hospital, Italy
    J Rheumatol 27:2621-3. 2000
    ....
  7. ncbi Myocardial involvement in systemic sclerosis
    L Belloli
    Rheumatology Unit, IRCCS Humanitas Clinical Institute, University of Milan, Milan, Italy
    Rheumatology (Oxford) 47:1070-2. 2008
    ..To identify clinical and/or laboratory characteristics that could be risk factors for myocardial microvascular involvement in patients with SSc...
  8. ncbi Interstitial lung disease in systemic sclerosis
    B Marasini
    Rheumatology Unit, Humanitas Clinical Institute, IRCCS, University of Milan, Italy
    Int J Immunopathol Pharmacol 20:223-8. 2007
    ..Future research should focus on new anti-inflammatory or immunosuppressive agents...
  9. ncbi Statins and cardiovascular risk in rheumatic diseases
    B Marasini
    Rheumatology Unit, IRCCS Humanitas Clinical Institute, Rozzano Milan, Italy
    Int J Immunopathol Pharmacol 25:25-30. 2012
    ..Larger trials are needed to refine the precise benefits and health-utility associated with this therapy...
  10. ncbi Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity
    M Massarotti
    Rheumatology Unit, IRCCS Humanitas Clinical Institute, University of Milan, Rozzano, Milan, Italy
    Int J Immunopathol Pharmacol 22:547-9. 2009
    ..We report the case of a patient with PsA who presented liver dysfunction during adalimumab, subsequently successfully treated with etanercept...